Pancreatic adenocarcinoma has a poor prognosis and frequently develops resistance to standard chemotherapeutics. Oncolytic adenoviruses represent a promising approach to overcome treatment resistance. The replication-selective dl922-947 adenovirus, defective in pRb binding, targets cancers with deregulated cell cycle control, such as the majority of pancreatic tumors. Cell killing efficacy was higher for dl922-947 than for adenovirus type 5 (Ad5) and the clinically approved dl1520 in pancreatic cancer cells with K-ras, p16 and p53 mutations. Combinations of dl922-947 and 5-fluorouracil or gemcitabine (2
Introduction
Pancreatic adenocarcinomas are, in the majority of cases, incurable. 1 Despite advances in diagnosis and staging, most pancreatic cancers are diagnosed when locally advanced or metastatic, resulting in poor treatment outcomes. Gemcitabine (2 0 2 0 -difluoro-2-deoxytidine) is currently the first-line therapy for advanced disease, with a modest survival benefit over 5-fluorouracil (5-FU), although resistance rapidly develops. [2] [3] [4] Combining gemcitabine with 5-FU improved survival in certain patients, 5 whereas combinations with other cytotoxic drugs resulted in negligible survival benefits. [6] [7] [8] Improved therapies with greater efficacy and different mechanisms of action are therefore needed.
Replication-selective oncolytic adenoviruses are a promising new class of antitumour agents for targeting of solid cancers. 9, 10 The first and most intensively investigated engineered mutant dl1520 was based on deletion of the E1B55K gene, thereby preventing p53 binding and degradation in normal cells. 11, 12 Later reports suggested that dl1520 was selective for cancer cells not only with a non-functional p53 pathway, but also with altered mRNA export functions complementing the lack of E1B55K. [12] [13] [14] To date, two mutants with the E1B55K gene deleted, ONYX-015 and H101 (Oncorine; Shanghai Sunway Biotech, Shanghai, China), have been evaluated in numerous clinical trials and H101 is now a licensed drug in China. 9, 15, 16 Safety and tumor selectivity were clearly demonstrated, whereas definite efficacy was achieved only in combination with cisplatin or 5-FU. 9, [15] [16] [17] [18] Modest responses were also reported with ONYX-015 in combination with gemcitabine in locally advanced pancreatic cancer 19 compared to trials with the virus alone. 20 A major cause for the limited efficacy with dl1520 mutants is that additional functions of the E1B55K protein are essential for the viral life cycle; replication was not only prevented in normal cells, but also severely attenuated in the majority of cancer cells, thereby limiting viral spread and efficacy. 13, 14, 21 More recently, oncolytic viruses with improved potency have been engineered, such as the E1ACR2-deleted mutants dl922-947 and AdD24. [22] [23] [24] The E1ACR2 region is essential for viral replication in normal cells through binding and inactivating of pRb forcing the S-phase entry to support viral replication. The majority of pancreatic adenocarcinomas have deregulated cell cycle control that complements the lack of E1A binding to pRb and allows viral production to proceed. As 80-95% of pancreatic cancers present with a loss of the cell cycle regulator p16 INK4A and/or have deregulated K-ras activity, [25] [26] [27] this cancer is a suitable target for E1ACR2-deleted mutants. Greater efficacy of dl922-947 compared to dl1520 has been reported in numerous solid malignancies in preclinical models. 22, [28] [29] [30] [31] Synergistic interactions were reported for an AdD24 mutant with irinotecan in glioblastoma cells and for dl922-947 with mitoxantrone or docetaxel in prostate cancer cells. 31, 32 A tropism-modified version, adenovirus type 5 (Ad5)/3-D24, induced synergistic effects with gemcitabine in ovarian cancer cell lines and increased efficacy in murine in vivo models, albeit with higher toxicity to normal tissue than that reported for dl1520. 33 Here we demonstrate that dl922-947 can potently induce cell death in pancreatic cancer models. When dl922-947 was combined with either 5-FU or gemcitabine, cell killing was greatly enhanced. Potent E1A expression was a requirement even in cells not supporting viral replication, in agreement with earlier reports. [34] [35] [36] Importantly, we demonstrate that E1A with the pRb-binding region deleted in dl922-947 can synergistically interact with 5-FU and gemcitabine in pancreatic cancer cells. Both replicationdependent and -independent mechanisms were indicated in the synergistic responses. High antitumour efficacy was seen in both drug-and virus-insensitive (Hs766T) andsensitive (Suit-2) cells with significantly longer time to tumor progression in vivo with the combination treatments. Interestingly, both 5-FU and gemcitabine increased cell surface expression of viral attachment and internalization receptors, the coxsackie and adenovirus receptor (CAR) and a v b 3 -and a v b 5 -integrins. The data presented here support further exploration of E1ACR2-deleted mutants for clinical development to treat pancreatic cancer.
Materials and methods

Cancer cell lines and adenoviruses
The human pancreatic cancer cell lines Suit-2, MIAPaCa-2 and Hs766T (Cell Services, Cancer Research-UK, London, UK) and murine Panc02 cells (kindly provided by Dr G Vassaux, Cancer Research-UK) were cultured in Dulbecco's modified Eagle's media supplemented with 10% fetal calf serum (PAA Laboratories, Oberosterreich, Austria). All cell lines were authenticated by STR profiling (Cell Services, Cancer Research-UK) at the end of the study and verified to be identical to profiles reported by ATCC (MIAPaCa-2, Hs766T) and to the original vials obtained from Cancer Research-UK (Suit-2). The following viruses and mutants were used: Ad5 (wild type), dl922-947 (DCR2, DE3B), dl1520 (DE1B55K, DE3B), dl312 (DE1A, DE3B) and Ad-GFP (CMV-GFP cassette replacing E1 region). All viruses used in this study had a viral particle to infectious unit ratio of 10-30 viral particles (vp) per PFU.
Cell killing assay and synergistic interactions Cells were plated at 1 Â 10 4 cells in 96-well plates and infected with viruses and/or treated with cytotoxic drugs 24 h later. Treated cells were assayed 7 days after seeding using the MTS assay (Promega, Southampton, UK) to quantify live cells, as an indirect measure of cell death. The concentration of each agent killing 50% of cells (50% effective concentration (EC 50 )) was calculated through the generation of dose-response curves using untreated cells as control as described previously. 35, 36 Fivefold dilutions were prepared starting at 1 Â 10 5 particles per cell (ppc) for all viruses and at 400 mM for gemcitabine (Eli Lilly, Basingstoke, Hampshire, UK) and 5-FU (Sigma Chemicals). Each data point was generated from triplicate samples in each assay, repeated 3-5 times. Synergy was determined by construction of isobolograms and calculation of combination indices (CIs) as described previously. 31, 36, 37 The interactions were defined as synergistic when CI values were less than the theoretical additive value, with data points below the line of additivity and antagonistic for data points above the line. CI values p0.9 indicate synergism, CIX1.1 antagonism and 0.9oCIo1.1 additive effects.
Adenovirus replication
Cells were treated with gemcitabine at 30 and 100 nM or 5-FU at 10 and 100 mM and infected with adenovirus and adenoviral mutants 24 h later at 10-1000 ppc. Cells and media were collected 48 h after infection, freeze-thawed and analyzed by the tissue culture inhibitory dose at 50% as described previously. 38 Each assay was repeated 2-3 times, including an internal control (Ad5), averaged and expressed as PFU ml
À1
.
Flow cytometry analysis
Cells were treated with drugs as described above for the replication assay, followed by infection with Ad-GFP at 10-100 ppc for 2 h. The cells were harvested 48 h after infection and the proportion of green fluorescent protein (GFP)-positive cells determined by flow cytometry (FACSCalibur instrument; Becton Dickinson, Oxford, UK), acquiring 10 000 events per sample from duplicate wells using propidium iodide (Sigma-Aldrich, Gillingham, Dorset, UK) to exclude dead cells. Analysis was by the CellQuest software (Becton Dickinson). For determination of CAR and integrin expression levels, cells were treated with drugs as above. After 48 h, cells were harvested, centrifuged, washed (phosphate-buffered saline, 2% fetal calf serum, 0.5 M EDTA (pH 8.0)) and incubated for 90 min with the respective antibody: mouse monoclonal anti-human CAR (ATCC) at a 1:500 dilution, mouse monoclonal anti-a v b 3 (LM609) or mouse monoclonal anti-a v b 5 (PIF6) both at 10 mg ml À1 (provided by Dr John Marshall, Cancer Research-UK). Antibody-bound samples were incubated with secondary polyclonal goat anti-mouse fluorescein isothiocyanate-conjugated antibody (Dako, St Thomas Place, Cambridgeshire, UK); controls were incubated in 5% goat serum alone and incubated with secondary antibody and propidium iodide. Samples were analyzed as above, in triplicate and repeated 2-3 times. 
Immunoblot analysis
Subconfluent cells were infected with viruses in the presence of gemcitabine and 5-FU at the concentrations described above. Cells were harvested at 24, 48 and 72 h post-infection, and lysed in buffer (50 mM HEPES (pH 7.4), 250 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM NaF, 1% Triton X-100) containing a protease inhibitor cocktail (Roche, Burgess Hill, West Sussex, UK). Total protein, 20 mg, was separated on sodium dodecyl sulfate-polyacrylamide gels under reducing conditions and transferred to polyvinylidene fluoride membranes (Millipore, Watford, UK). Viral and cellular proteins were detected by the following anti-sera: rabbit anti-Ad2 E1A at 1:1000 (SC-430; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-penton at 1:2500 (gift Novartis-GTI, Emeryville, CA, USA) and goat anti-actin at 1:1000 (SC-1615; Santa Cruz Biotechnology). Detection was by horseradish peroxidase-conjugated secondary rabbit anti-mouse immunoglobulin G, goat anti-rabbit immunoglobulin G, rabbit anti-goat immunoglobulin G (Dako) and chemiluminescence reagent (Amersham/Pharmacia, Buckinghamshire, UK), followed by autoradiography (BioMax film; Kodak, Geneva, Switzerland).
In vivo tumor growth
Tumors were grown in one flank of C57BL athymic (ICRF nu/nu) mice by subcutaneous implantation of 1 Â 10 6 Suit-2 cells. The Hs766T cells were mixed 1:1 with Matrigel (BD Biosciences, Oxford, UK) and 1 Â 10 6 were implanted in each flank. Dose-responses to viral mutants or gemcitabine were determined by administration of virus intratumorally at 1 Â 10 9 -5 Â 10 10 vp per injection on days 1, 3 and 5 or gemcitabine at 31-500 mg kg À1 intraperitoneally on days 1, 4, 7 and 11. Suboptimal doses of virus at 1 Â 10 10 vp per injection and gemcitabine at 62 mg kg À1 were selected to enable the detection of additive or synergistic effects in response to combination treatments. Tumor volumes were estimated twice weekly: volume ¼ (length Â width 2 Â p)/6. Treatments were initiated when tumors were 100±20 ml with tumor growth and progression followed until tumors reached 1.44 cm 2 or until symptomatic tumor ulceration occurred (according to UK Home Office Regulations). Treatment groups were balanced by tumor size at the time of treatment initiation in all cases (t-test for tumor volumes, P40.8). Survival analysis expressed as time to progression (tumor volume X500 ml) was performed according to the method of Kaplan-Meier (log-rank test for statistical significance). Tumor growth curves were compared using one-way analysis of variance and P-values o0.05 were considered significant.
Results
The oncolytic dl922-947 mutant has higher cell killing potency in human pancreatic cancer cells than either wild-type virus or the clinically approved dl1520 mutant The efficacy of dl922-947 was higher than that of Ad5 in all human cell lines, whereas dl1520 was less potent, except in the Hs766T cells ( Figure 1a ). The Suit-2 cells were most sensitive to virus-induced cell death with EC 50 values of 34.3 ± 3.5 ppc for Ad5, 14.6 ± 4.8 ppc for dl922-947 and 115±18.6 ppc for dl1520 with similar values in MIAPaCa-2 cells. The Hs766T cells were highly insensitive to virusinduced cell killing with EC 50 values of 24 400 ± 8000, 17 400±5800 and 15 000±3000 ppc for Ad5, dl922-947 and dl1520, respectively. There were no significant differences between viruses in the murine Panc02 cells (EC 50 values of 2000 ppc) (Figure 1a ). The non-replicating E1A-deleted mutant dl312 did not induce cell death at concentrations up to 1 Â 10 5 ppc in any cell line. Interestingly, the Suit-2 cells were highly sensitive to gemcitabine (18±1 nM), but relatively resistant to 5-FU-(435 mM) induced cell death. The MIAPaCa-2 cells were relatively sensitive to both gemcitabine (203 ± 90 nM) and 5-FU (830±42 nM), whereas the Hs766T cells were the least sensitive with o50% of cells killed at the highest concentrations of drugs at 400 mM. The murine Panc02 cells showed average sensitivity to both drugs with EC 50 values of 53 ± 3 and 1026 ± 194 nM for gemcitabine and 5-FU, respectively.
Wild-type virus and dl922-947 synergistically enhance cell killing in combination with 5-FU or gemcitabine, both in drug-sensitive and -insensitive pancreatic cancer cells To investigate whether pancreatic cancer cells could be sensitized to drugs by oncolytic adenoviruses, low doses of 5-FU or gemcitabine (pEC 30 value) were added with low doses of virus. Cell killing was greatly increased to more than additive levels in all tested cell lines treated with Ad5 or dl922-947 in combination with 5-FU or gemcitabine (Figures 1b and c) . To determine whether virus and drugs interacted synergistically, the combinations were tested over a range of fixed ratios to generate quantitative CI values. The most potent synergistic responses were seen with 5-FU in Suit-2 cells where simultaneous Ad5 infection and 5-FU addition resulted in CI values p0.14 ( Table 1) . Strong synergy was also observed with gemcitabine, although the CI values were slightly higher at CI p0.71 (Table 1 and Figure 1d , upper panels). Drug combinations with the dl922-947 mutant resulted in similar potent synergistic cell killing with CI values p0.6 for both gemcitabine and 5-FU in the Suit-2 cells (Figure 1d , lower panels and Supplementary Table  S1 ). In the MIAPaCa-2 and Panc02 cells, 50% of the combinations at the tested ratios were synergistic with either drug (Table 1) . To explore whether the synergy could be further improved, the order of addition of virus and gemcitabine was altered in Suit-2 cells (Supplementary Table S1 ). Synergy was observed in 10 out of 12 test conditions with either dl922-947 or Ad5, independently of scheduling with simultaneous additions causing the greatest effects. Combinations with the non-replicating dl312 mutant caused no increase in drug-induced cell death (data not shown). For the highly drug-insensitive Hs766T cells, isobolograms could not be constructed; however, combinations of dl922-947 with 5-FU or gemcitabine over a range of fixed concentrations dl922-947 synergizes with DNA-damaging drugs M Bhattacharyya et al resulted in clearly synergistic increases in cell killing (Figure 1e ). In conclusion, both Ad5 and dl922-947 increased cell killing to more than the expected additive levels in all tested cell lines, with no significant differences between viruses (shown for Suit-2, Hs766T and Panc02).
Gemcitabine and 5-FU increase viral uptake and cellular receptors essential for the internalization of adenovirus To test whether the observed synergy was due to increased permissiveness to adenoviral infection in the presence of (Table 1) . Cells were analyzed for viability as described above, one representative study out of three. The straight lines illustrate the theoretical additive effects.
(e) Hs766T cells were infected with dl922-947 and treated with 5-FU or gemcitabine at fixed doses killing o20% of cells alone. Doses were as indicated, in particles per cell (ppc) for virus and nM for drugs. Cell viability determined as described above, averages±s.e.m., n ¼ 3, *Po0.05 for combination treated cells compared with the theoretical additive effects (indicated by the dashed lines).
cytotoxic drugs, cells were infected with a non-replicating GFP-expressing virus to monitor viral uptake. The MIAPaCa-2 cells were the most and Hs766T cells the least infectable (Figure 2a ). All cell lines demonstrated dose-dependent increases in viral uptake from 10 to 100 ppc (not shown). In the presence of low doses (oEC 30 ) of 5-FU or gemcitabine significant increase in viral uptake were observed in all cell lines (Po0.05) ( Figure 2a) . Next, we examined whether expression levels of the viral attachment receptor CAR and the major internalization receptors a v b 3 -and a v b 5 -integrins were increased in response to the cytotoxic drug treatments causing the higher viral uptake. In untreated Hs766T cells, baseline CAR membrane levels were lower than in Suit-2, 4 ± 4% and 71 ± 5%, respectively, and might explain the reduced cytotoxicity and poor infectability of this cell line (Figures 2b and c) . However, after prolonged (472 h) growth in culture, CAR expression increased in untreated Hs766T cells to levels similar to those in MIAPaCa-2 cells (40-50%; not shown), although no parallel increase in infectability was detected. Treatment with 5-FU or gemcitabine significantly increased the cell surface expression levels of CAR in Hs766T cells, but not in Suit-2 cells (Po0.001) (Figures 2b and c) . Cell surface expression of both integrins was significantly increased in Suit-2 and Hs766T cells in the presence of cytotoxic drugs (Po0.001) (Figure 2b and c). Similar increases in integrin expression also occurred in MIAPaCa-2 cells (not shown).
Although a v b 3 levels were o3% in untreated Suit-2 cells, a v b 5 was expressed at higher levels. In contrast, in the Hs766T cells a v b 3 was higher (12 ± 3%) than the a v b 5 expression (5 ± 2%).
Viral replication is decreased in spite of potent early viral gene expression in response to 5-FU and gemcitabine
We further explored whether potential drug-induced effects on the viral life cycle such as early and late viral gene expression or replication could be involved in the enhancement of cell killing with the combination treat- 3 PFU per cell) for both Ad5 and dl922-947. When cells were pretreated with 5-FU or gemcitabine at 10 mM and 30 nM, respectively, replication was not significantly affected by either drug in Hs766T cells, whereas 5-FU attenuated replication in Suit-2 cells for both viruses (Figures 3a and b) . In the presence of higher doses of drugs at 100 mM (5-FU) and 100 nM (gemcitabine), replication was attenuated in both cell lines with Ad5 and to a lesser degree with the dl922-947 mutant (Figures  3a and b) . The attenuated replication was paralleled by a decrease in the expression of late proteins such as penton, whereas E1A expression was elevated or unaffected as expected from the higher infectability in the presence of drugs (Figures 3c and d ). Viral replication was not supported in the murine Panc02 cells despite potent expression of E1A and good sensitization in response to the combination treatments. E1A expression was also increased in the presence of the drugs in MIAPaCa-2 and Panc02 cells (not shown). Taken together, these data suggest that E1A can potently sensitize pancreatic cancer cells to the effects of cytotoxic drugs even when viral replication is attenuated or prevented.
Inhibition of tumor growth and prolonged survival in Suit-2 and Hs766t tumor xenograft models in response to the dl922-947 mutant Good efficacy was demonstrated in the murine immunedeficient Hs766T xenograft model with dl922-947 and to a lesser degree with Ad5 virus with median survival of 69 and 15 days, respectively (mock treated 8 days) (Figure 4a ). Combination studies with drugs could not be evaluated in animals with Hs766T xenografts owing to drug toxicity using the higher doses required for efficacy in this model. However, in the Suit-2 model efficacy was greatly improved when suboptimal doses of gemcitabine and the dl922-947 mutant were combined (Figures 4b and c and Table 2 ). No significant efficacy with wild-type virus, either alone or in combination with gemcitabine, was observed under the same conditions, whereas higher doses resulted in limited tumor regression ( Table 2 , study 1). The non-replicating control virus (dl312) either alone or in combination with gemcitabine had no efficacy (Figures 4b and c and Table 2 ). The combination treatments were well tolerated with no early deaths due to toxicity. In all, 7 of 11 mice in this combination group were alive at the end of the study (day 85) and median survival was consequently greater than 85 days, compared to 39 and 48 days for gemcitabine-and dl922-947-treated groups respectively (Po0.001) (Figure 4c and Table 2 ). dl922-947 synergizes with DNA-damaging drugs M Bhattacharyya et al
Discussion
The prognosis for pancreatic adenocarcinoma is still dismal despite the improved treatment options during the past decades. Currently, the survival rate is less than 3% for this cancer. 1, 4 To develop novel curative treatments is therefore a priority. The findings presented here suggest that oncolytic replication-selective mutants with the E1ACR2 deletion (for example, dl922-947, AdD24, AdDD) are suitable candidates for further clinical developments. Because of the CR2 deletion, these mutants are unable to inactivate pRb and cannot force normal cells to enter the S phase. 22, 23 However, the majority of pancreatic adenocarcinomas have deregulated cell cycle control through activating ras mutations and/or inactivation of p16 and p53, 26, 27 thus enabling viral replication to proceed. Although dl922-947 and other E1ACR2 mutants have been demonstrated to be as efficient as wild-type virus in eliminating a great variety of tumor types and cancer cells, 22, 23, 28, 30, 39, 40 this is to our knowledge the first systematic investigation of cell killing and efficacy in pancreatic cancer cells. We selected the human Suit-2 and MIAPaCa-2 cells (both with K-ras activation, p16null and p53mut) to represent typical pancreatic adenocarcinomas and Hs766T with numerous gene deletions and alterations such as downregulated p21, BUB1 mutations and defective mitotic spindle checkpoint, but with wild-type p53. 25, 41, 42 The murine pancreatic ductal metastatic adenocarcinoma cell line Panc02 43 was included with the idea to investigate efficacy in immunocompetent animals. However, owing to the aggressive growth of the tumor xenografts and the lack of viral replication in these cells, significant efficacy could not be achieved in vivo.
We demonstrated that cell killing efficacy of dl922-947 was greater than that of Ad5 in all tested cell lines as previously reported for non-pancreatic cancer cells. 22, [28] [29] [30] 44 In contrast, the prototype oncolytic adenovirus dl1520 was significantly less potent than Ad5 in the majority of cell lines, but surprisingly not in Hs766T that express p53. However, the major determinants for efficient replication of the dl1520 mutant appear to be altered nuclear mRNA export in cancer cells. 13, 14 Thus, the differences in potency for dl922-947 and dl1520 in Suit-2, MIAPaCa-2 and H460 cells are most likely caused by less efficient complementation of nuclear mRNA export functions in these cells than in Hs766T. The higher resistance to the DNA-damaging drugs in Hs766T cells might be a consequence of intact p53 expression and DNA-repair functions and/or the ability to overcome mitotic checkpoints (BUB1 mutations). 41 Nevertheless, combining virus and drugs sensitized both drug/virus-insensitive Hs766T and -sensitive Suit-2 and MIAPaCa-2 cells, resulting in greatly enhanced cell death. In fact, up to 80% of Hs766T cells were eliminated when dl922-947 and drugs were combined at doses that killed less than 20% of cells when administered alone. The À1 on days 2, 4, 7 and 11. Control groups were treated with phosphate-buffered saline (PBS) (mock) and dl312. (b) Tumor volumes expressed in ml, averages±s.e.m., 10-11 animals per group, **Po0.001). (a, c) Kaplan-Meier survival curves generated from tumor progression data (o525 ml), combination treated animals had significantly longer time to progression than the corresponding single agent-treated animals, **Po0.001. Abbreviation: vp, viral particles. All viruses administered intratumorally at 1 Â 10 10 vp per injection on days 1, 3 and 5. Gemcitabine administered intraperitoneally at 62 (G62) and 125 (G125) mg kg À1 on days 2, 4, 7 and 11. Data from two separate studies (1) and (2) with 10-11 animals per group; study (2) is also illustrated in Figures 4b and c. dl922-947 synergizes with DNA-damaging drugs M Bhattacharyya et al greatest effects were observed in the presence of 5-FU. In Suit-2 cells, the synergistic effects were greater in combination with 5-FU, whereas in MIAPaCa-2 and Panc02 cells, both drugs caused similar levels of synergy.
Reasons for the different degrees of synergy include the genetic background of each cell line that is likely to influence drug metabolism and progression of the viral life cycle, in addition to genetic alterations that affect apoptosis and DNA-repair functions. Furthermore, both viral uptake and expression levels of receptors varied widely between cell lines. Expression of the integrin a v b 5 and CAR was lowest in Hs766T cells and highest in Suit-2 cells that also had higher levels of viral uptake.
In the presence of 5-FU or gemcitabine, both viral uptake and the receptor levels increased in all cell lines and likely contributed to the higher cell killing efficacy. Although the increases in viral uptake were statistically significant in all cells, the total levels remained very low in the Hs766T cells (o3% of cells) and the potent synergistic cell killing might not be explained by increased viral uptake in these cells. However, absolute levels of viral receptors may not be a limiting factor for infection once a minimum level of expression has been reached as previously observed in pancreatic and lung cancer cells. 45 Despite increased viral uptake in the presence of drugs, replication was not increased, but rather attenuated. Inhibition of viral replication was previously demonstrated with gemcitabine during the early phases of viral replication despite enhancement of drug-induced cell killing. 33, 35 Most likely, 5-FU and gemcitabine prevent efficient viral DNA synthesis by causing DNA damage to both the host and viral genome, an effect that would be detrimental for virus production at higher drug doses. Inhibition of replication was not significant at lower doses o30 nM for either drug, except in the more drug-sensitive Suit-2 cells, while replication in the drug-insensitive Hs766T cells was less attenuated, especially when infected with dl922-947. Interestingly, enhancement of druginduced cell killing was also seen in the Panc02 cells with all viruses, even though these cells did not support viral replication as expected for the majority of murine cells. 46, 47 We speculate that early viral E1A expression was responsible for most of the synergistic effects based on the fact that E1A is a potent apoptosis inducer and synergizes with apoptosis-inducing cytotoxic drugs. [34] [35] [36] 48 Adenoviral E1A proteins can interact with numerous cellular effector molecules such as tumor necrosis factora, NO, TNF-related apoptosis-inducing ligand, Fas ligand (reviewed in ref. 49 ) and immune cells, including NK cells, macrophages and T cells, promoting apoptosis. 34, 50, 51 In fact, local administration of the E1A gene alone, expressed from plasmids delivered in liposome coating, has been evaluated in clinical trials phase I and II targeting ovarian, breast and head and neck cancers and was deemed safe with promising future applications. [52] [53] [54] However, as the spread of E1A expressed from this nonreplicating vector was limited to the site of delivery, significant efficacy was not demonstrated in these trials. Although in preclinical studies antitumour efficacy was reported and could be greatly increased in combination with cytotoxic drugs, the sensitization of tumor cells to E1A expression was suggested to occur through a number of mechanisms, for example, induction of procaspases, activation of p38 and modifications of Her2/neu, p300/CBP, pRb and p21 activities. 34, [55] [56] [57] It was also suggested that E1A induces mesenchymal-toepithelial conversion, resulting in the formation of gap junctions, in turn facilitating the cell-to-cell transfer of small cytotoxic drugs, such as gemcitabine and 5-FU. 57 In this study, we verified that E1A was expressed at high levels in the presence of both drugs in parallel to the increased infectability. In contrast, late viral gene expression such as penton was decreased or low at the higher concentrations, as expected from the attenuated viral replication. On the basis of these findings, we propose that E1A expression is essential for sensitization to drugs in the tested pancreatic cell lines. This hypothesis was further verified by the potent synergy in the murine Panc02 cells that support E1A expression as early as 6 h after infection, but not replication and the lack of sensitization with the E1A-deleted mutant dl312. However, in our in vivo models, both replication and E1A expression contributed to the superior efficacy with dl922-947 both in Hs766T and Suit-2 tumor xenografts. When combined with gemcitabine, significant tumor growth inhibition and prolonged survival was noted, most likely caused by a combination of E1A-enhanced drug-induced cell killing and viral replication and spread within the tumors.
We have demonstrated that despite the variations in the degree of synergy and cell killing, all pancreatic cell lines in this study could be efficiently eliminated with the dl922-947 mutant both alone and in combination with gemcitabine or 5-FU. The observed differences likely reflect the heterogeneity of pancreatic cancers and highlight the challenges in overcoming resistance to conventional chemotherapy. We identified the dl922-947 oncolytic mutant, with the pRb-binding domain deleted, as possible chemosensitizer for the treatment of advanced pancreatic cancer. Notably, the first clinical evaluation of another E1ACR2-deleted mutant, Ad5-D24RGD, was recently completed in a phase I trial for recurrent malignant gliomas (http://clinicaltrialsfeeds.org/ clinical-trials/show/NCT00805376). Safety and toxicity data from this trial are eagerly awaited for guidance on future developments of E1ACR2-deleted mutants into optimized clinical agents. We conclude that our data presented here, together with findings from other recent reports, strongly support further development of E1ACR2-deleted mutants as highly suitable candidates to treat pancreatic cancer based on the potent cell killing efficacy and the strong synergistic interactions with DNAdamaging drugs.
